Pfizer's dual-acting β2 agonists/muscarinic M3 antagonists

被引：0

作者：

Norman, Peter ^{[1
]}

机构：

[1] Norman Consulting, Burnham SL1 8JW, Bucks, England

来源：

EXPERT OPINION ON THERAPEUTIC PATENTS | 2008年 / 18卷 / 09期

关键词：

asthma; beta(2) agonist; bronchodilator; COPD; M3; antagonist; MABA; muscarinic antagonist;

D O I：

10.1517/13543776.18.9.1091

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Bifunctional aromatic compounds that contain both beta(2) agonist and muscarinic antagonist pharmacophores linked by a flexible lipophilic spacer are claimed. The compounds display nanomolar potency with respect to both activities and appear designed to provide a long duration of action. The compounds are claimed to be useful in the treatment of both asthma and chronic obstructive pulmonary disease.

引用

页码：1091 / 1096

页数：6

共 50 条

[31] The effect of absolute configuration on activity, subtype selectivity (M3/M2) of 3α-acyloxy-6β-acetoxyltropane derivatives as muscarinic M3 receptor antagonists
Wang, Zhi-Peng
Liu, Hui-Zhong
Zhu, Liang
Hu, You-Min
Cui, Yong-Yao
Niu, Yin-Yao
Lu, Yang
Chen, Hong-Zhuan
BIOORGANIC & MEDICINAL CHEMISTRY, 2013, 21 (05) : 1234 - 1239
[32] Shared binding modes of M3 muscarinic agonists and antagonists may incentivize development of novel IOP-reducing drugs.
Kim, Minjae James
Ibrahim, Mohamed
Jablonski, Monica M.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2024, 65 (07)
[33] Structure-guided development of selective M3 muscarinic acetylcholine receptor antagonists
Liu, Hongtao
Hofmann, Josefa
Fish, Inbar
Schaake, Benjamin
Eitel, Katrin
Bartuschat, Amelie
Kaindl, Jonas
Rampp, Hannelore
Banerjee, Ashutosh
Huebner, Harald
Clark, Mary J.
Vincent, Sandra G.
Fisher, John T.
Heinrich, Markus R.
Hirata, Kunio
Liu, Xiangyu
Sunahara, Roger K.
Shoichet, Brian K.
Kobilka, Brian K.
Gmeiner, Peter
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2018, 115 (47) : 12046 - 12050
[34] The scientific rationale for combining long-acting β2-agonists and muscarinic antagonists in COPD
Cazzola, Mario
Molimard, Mathieu
PULMONARY PHARMACOLOGY & THERAPEUTICS, 2010, 23 (04) : 257 - 267
[35] Regiospecific Introduction of Halogens on the 2-Aminobiphenyl Subunit Leading to Highly Potent and Selective M3 Muscarinic Acetylcholine Receptor Antagonists and Weak Inverse Agonists
Fischer, Oliver
Hofmann, Josefa
Rampp, Hannelore
Kaindl, Jonas
Pratsch, Gerald
Bartuschat, Amelie
Taudte, R. Verena
Fromm, Martin F.
Huebner, Harald
Gmeiner, Peter
Heinrich, Markus R.
JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (08) : 4349 - 4369
[36] M1 AND M3 MUSCARINIC ANTAGONISTS INHIBIT HUMAN NASAL GLANDULAR SECRETION INVITRO
MULLOL, J
BARANIUK, JN
LOGUN, C
MERIDA, M
HAUSFELD, J
SHELHAMER, JH
KALINER, MA
JOURNAL OF APPLIED PHYSIOLOGY, 1992, 73 (05) : 2069 - 2073
[37] Mode of interaction of 1,4-dioxane agonists at the M2 and M3 muscarinic receptor orthosteric sites
Del Bello, Fabio
Bonifazi, Alessandro
Quaglia, Wilma
Mazzolari, Angelica
Barocelli, Elisabetta
Bertoni, Simona
Matucci, Rosanna
Nesi, Marta
Piergentili, Alessandro
Vistoli, Giulio
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, 24 (15) : 3255 - 3259
[38] Industrially Viable Preparation of (R)-3-Quinuclidinol, a Key Building Block of Muscarine M1, M3 Agonists and M3 Antagonists
Chavakula, Ramadas
Mutyala, Narayana Rao
Chennupati, Srinivasa Rao
ORGANIC PREPARATIONS AND PROCEDURES INTERNATIONAL, 2013, 45 (06) : 507 - 509
[39] Muscarinic agonists and antagonists in the treatment of Alzheimer's disease
Greenlee, W
Clader, J
Asberom, T
McCombie, S
Ford, J
Guzik, H
Kozlowski, J
Li, S
Liu, C
Lowe, D
Vice, S
Zhao, H
Zhou, G
Billard, W
Binch, H
Crosby, R
Duffy, R
Lachowicz, J
Coffin, V
Watkins, R
Ruperto, V
Strader, C
Taylor, L
Cox, K
FARMACO, 2001, 56 (04): : 247 - 250
[40] Muscarinic M1 receptor agonists and M2 receptor antagonists as therapeutic targets in Alzheimer's disease
Sheardown, MJ
EXPERT OPINION ON THERAPEUTIC PATENTS, 2002, 12 (06) : 863 - 870

← 1 2 3 4 5 →